Compare USNA & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | GLSI |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | 1570 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.7M | 327.2M |
| IPO Year | 1996 | 2020 |
| Metric | USNA | GLSI |
|---|---|---|
| Price | $18.81 | $27.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 97.1K | ★ 100.3K |
| Earning Date | 05-05-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,060,902,000.00 | N/A |
| Revenue This Year | $3.90 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $45.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.60 | $7.78 |
| 52 Week High | $38.32 | $34.10 |
| Indicator | USNA | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 60.93 |
| Support Level | $16.77 | $20.86 |
| Resistance Level | $21.16 | $29.89 |
| Average True Range (ATR) | 0.94 | 1.66 |
| MACD | -0.01 | 0.44 |
| Stochastic Oscillator | 45.54 | 82.70 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.